Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma
Abstract
:1. Introduction
2. Materials and Methods
Statistics
3. Results
3.1. General Cohort Characteristics
3.2. Survival
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Al-Qurayshi, Z.; Smith, R.; Walsh, J.E. Sinonasal Squamous Cell Carcinoma Presentation and Outcome: A National Perspective. Ann. Otol. Rhinol. Laryngol. 2020, 129, 1049–1055. [Google Scholar] [CrossRef] [PubMed]
- Mody, M.D.; Saba, N.F. Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment. Curr. Treat. Options Oncol. 2020, 21, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Elgart, K.; Faden, D.L. Sinonasal Squamous Cell Carcinoma: Etiology, Pathogenesis, and the Role of Human Papilloma Virus. Curr. Otorhinolaryngol. Rep. 2020, 8, 111–119. [Google Scholar] [CrossRef] [PubMed]
- Riobello, C.; Vivanco, B.; Reda, S.; López-Hernández, A.; García-Inclán, C.; Potes-Ares, S.; Cabal, V.N.; López, F.; Llorente, J.L.; Hermsen, M.A. Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer. Head Neck 2018, 40, 818–827. [Google Scholar] [CrossRef] [PubMed]
- Jafri, S.H.; Shi, R.; Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC Cancer 2013, 13, 158. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kusunoki, K.; Toiyama, Y.; Okugawa, Y.; Yamamoto, A.; Omura, Y.; Ohi, M.; Araki, T.; Kusunoki, M. Advanced Lung Cancer Inflammation Index Predicts Outcomes of Patients With Colorectal Cancer After Surgical Resection. Dis. Colon Rectum 2020, 63, 1242–1250. [Google Scholar] [CrossRef]
- Kobayashi, S.; Karube, Y.; Inoue, T.; Araki, O.; Maeda, S.; Matsumura, Y.; Chida, M. Advanced Lung Cancer Inflammation Index Predicts Outcomes of Patients with Pathological Stage IA Lung Adenocarcinoma Following Surgical Resection. Ann. Thorac. Cardiovasc. Surg. 2019, 25, 87–94. [Google Scholar] [CrossRef] [Green Version]
- Barth, D.A.; Brenner, C.; Riedl, J.M.; Prinz, F.; Klocker, E.V.; Schlick, K.; Kornprat, P.; Lackner, K.; Stöger, H.; Stotz, M.; et al. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Cancer Med. 2020, 9, 5473–5479. [Google Scholar] [CrossRef] [PubMed]
- Jank, B.J.; Kadletz, L.; Schnöll, J.; Selzer, E.; Perisanidis, C.; Heiduschka, G. Prognostic value of advanced lung cancer inflammation index in head and neck squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2019, 276, 1487–1492. [Google Scholar] [CrossRef] [PubMed]
- Gaudioso, P.; Borsetto, D.; Tirelli, G.; Tofanelli, M.; Cragnolini, F.; Menegaldo, A.; Fabbris, C.; Molteni, G.; Marchioni, D.; Nicolai, P.; et al. Advanced lung cancer inflammation index and its prognostic value in HPV-negative head and neck squamous cell carcinoma: A multicentre study. Support. Care Cancer 2021, 29, 4683–4691. [Google Scholar] [CrossRef]
- Tsai, Y.T.; Hsu, C.M.; Chang, G.H.; Tsai, M.S.; Lee, Y.C.; Huang, E.I.; Lai, C.H.; Fang, K.H. Advanced Lung Cancer Inflammation Index Predicts Survival Outcomes of Patients With Oral Cavity Cancer Following Curative Surgery. Front. Oncol. 2021, 11, 609314. [Google Scholar] [CrossRef] [PubMed]
- Topkan, E.; Ozdemir, Y.; Kucuk, A.; Guler, O.C.; Sezer, A.; Besen, A.A.; Mertsoylu, H.; Senyurek, S.; Kilic Durankus, N.; Bolukbasi, Y.; et al. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Definitive Concurrent Chemoradiotherapy. J. Oncol. 2020, 2020, 3127275. [Google Scholar] [CrossRef] [PubMed]
- Fearon, K.C.; Falconer, J.S.; Slater, C.; McMillan, D.C.; Ross, J.A.; Preston, T. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann. Surg. 1998, 227, 249–254. [Google Scholar] [CrossRef] [PubMed]
- Hébuterne, X.; Lemarié, E.; Michallet, M.; de Montreuil, C.B.; Schneider, S.M.; Goldwasser, F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J. Parenter. Enter. Nutr. 2014, 38, 196–204. [Google Scholar] [CrossRef] [PubMed]
- McRackan, T.R.; Watkins, J.M.; Herrin, A.E.; Garrett-Mayer, E.M.; Sharma, A.K.; Day, T.A.; Gillespie, M.B. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope 2008, 118, 1180–1185. [Google Scholar] [CrossRef]
- Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-related inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef]
- Zhong, B.; Deng, D.; Du, J.T.; Chen, F.; Liu, Y.F.; Liu, S.X. Prognostic Value Of The Preoperative Neutrophil To Lymphocyte Ratio In Patients With Sinonasal Squamous Cell Carcinoma. Cancer Manag Res. 2019, 11, 9733–9741. [Google Scholar] [CrossRef] [Green Version]
- Cupp, M.A.; Cariolou, M.; Tzoulaki, I.; Aune, D.; Evangelou, E.; Berlanga-Taylor, A.J. Neutrophil to lymphocyte ratio and cancer prognosis: An umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 2020, 18, 360. [Google Scholar] [CrossRef]
- Brkic, F.F.; Kadletz, L.; Jank, B.; Mayer, C.; Heiduschka, G.; Brunner, M. Impact of pretherapeutic neutrophil-to-lymphocyte ratio, serum albumin, body-mass index, and advanced lung cancer inflammation index on clinical outcome in sinonasal squamous cell carcinoma. J. Craniomaxillofac. Surg. 2020, 48, 33–37. [Google Scholar] [CrossRef]
- Huang, S.H.; O’Sullivan, B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr. Treat. Options Oncol. 2017, 18, 40. [Google Scholar] [CrossRef]
- Gangl, K.; Janik, S.; Nemec, U.; Nemec, S.; Erovic, B.M. Sinonasal carcinoma and Ohngren’s line: Retrospective cohort study of 39 patients. Clin. Otolaryngol. 2021, 46, 1153–1158. [Google Scholar] [CrossRef] [PubMed]
- Hum, A.; Wong, Y.K.Y.; Yee, C.M.; Lee, C.S.; Wu, H.Y.; Koh, M.Y.H. PROgnostic Model for Advanced Cancer (PRO-MAC). BMJ Support. Palliat. Care 2020, 10, e34. [Google Scholar] [CrossRef] [PubMed]
- Repo, H.; Löyttyniemi, E.; Kurki, S.; Kallio, L.; Kuopio, T.; Talvinen, K.; Kronqvist, P. A prognostic model based on cell-cycle control predicts outcome of breast cancer patients. BMC Cancer 2020, 20, 558. [Google Scholar] [CrossRef]
- Mahar, A.L.; Compton, C.; Halabi, S.; Hess, K.R.; Weiser, M.R.; Groome, P.A. Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J. Surg. Oncol. 2017, 116, 969–982. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://www.cancer.net/cancer-types/nasal-cavity-and-paranasal-sinus-cancer/stages-and-grades (accessed on 8 October 2022).
- Diem, S.; Schmid, S.; Krapf, M.; Flatz, L.; Born, D.; Jochum, W.; Templeton, A.J.; Früh, M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017, 111, 176–181. [Google Scholar] [CrossRef]
- Sun, Y.; Zhang, Y.; Huang, Z.; Lin, H.; Lu, X.; Huang, Y.; Chi, P. Combination of Preoperative Plasma Fibrinogen and Neutrophil-to-Lymphocyte Ratio (the F-NLR Score) as a Prognostic Marker of Locally Advanced Rectal Cancer Following Preoperative Chemoradiotherapy. World J. Surg. 2020, 44, 1975–1984. [Google Scholar] [CrossRef] [PubMed]
- Brkic, F.F.; Kadletz, L.; Jank, B.; Cede, J.; Seemann, R.; Schneider, S.; Haymerle, G.; Parzefall, T.; Kenner, L.; Heiduschka, G. Pretreatment assessment of hematologic and inflammatory markers in adenoid cystic carcinoma: Neutrophil/lymphocyte ratio is associated with multiple recurrences. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019, 127, 408–416. [Google Scholar] [CrossRef]
- Cao, Z.; Ji, J.; Zhang, C.; Wang, F.; Xu, H.; Yu, Y.; Sun, Y. The preoperative neutrophil-to-lymphocyte ratio is not a marker of prostate cancer characteristics but is an independent predictor of biochemical recurrence in patients receiving radical prostatectomy. Cancer Med. 2019, 8, 1004–1012. [Google Scholar] [CrossRef]
- Homa-Mlak, I.; Brzozowska, A.; Mlak, R.; Szudy-Szczyrek, A.; Małecka-Massalska, T. Neutrophil-to-Lymphocyte Ratio as a Factor Predicting Radiotherapy Induced Oral Mucositis in Head Neck Cancer Patients Treated with Radiotherapy. J. Clin. Med. 2021, 10, 4444. [Google Scholar] [CrossRef]
- Friedl, M.; Stoiber, S.; Brkic, F.F.; Kadletz-Wanke, L. Pretherapeutic Serum Albumin as an Outcome Prognosticator in Head and Neck Adenoid-Cystic Carcinoma. Biomedicines 2022, 10, 191. [Google Scholar] [CrossRef]
- Hennessey, P.T.; Reh, D.D. Chapter 9: Benign sinonasal neoplasms. Am. J. Rhinol. Allergy 2013, 27 (Suppl. S1), S31–S34. [Google Scholar] [CrossRef] [PubMed]
- Burges Watson, D.L.; Campbell, M.; Hopkins, C.; Smith, B.; Kelly, C.; Deary, V. Altered smell and taste: Anosmia, parosmia and the impact of long COVID-19. PLoS ONE 2021, 16, e0256998. [Google Scholar] [CrossRef] [PubMed]
- Kuroda, D.; Sawayama, H.; Kurashige, J.; Iwatsuki, M.; Eto, T.; Tokunaga, R.; Kitano, Y.; Yamamura, K.; Ouchi, M.; Nakamura, K.; et al. Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer 2018, 21, 204–212. [Google Scholar] [CrossRef] [Green Version]
- Bandera, E.V.; Lee, V.S.; Qin, B.; Rodriguez-Rodriguez, L.; Powell, C.B.; Kushi, L.H. Impact of body mass index on ovarian cancer survival varies by stage. Br. J. Cancer 2017, 117, 282–289. [Google Scholar] [CrossRef]
- Cantini, L.; Pistelli, M.; Merloni, F.; Fontana, A.; Bertolini, I.; De Angelis, C.; Bastianelli, L.; Della Mora, A.; Santinelli, A.; Savini, A.; et al. Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Clin. Breast Cancer 2020, 20, e89–e98. [Google Scholar] [CrossRef]
- Xie, H.; Wei, L.; Tang, S.; Gan, J. Prognostic Value of Pretreatment Albumin-to-Alkaline Phosphatase Ratio in Cancer: A Meta-Analysis. BioMed Res. Int. 2020, 2020, 6661097. [Google Scholar] [CrossRef]
- Liu, M.; Wang, L. Prognostic significance of preoperative serum albumin, albumin-to-globulin ratio, and prognostic nutritional index for patients with glioma: A meta-analysis. Medicine 2020, 99, e20927. [Google Scholar] [CrossRef]
- Danan, D.; Shonka, D.C., Jr.; Selman, Y.; Chow, Z.; Smolkin, M.E.; Jameson, M.J. Prognostic value of albumin in patients with head and neck cancer. Laryngoscope 2016, 126, 1567–1571. [Google Scholar] [CrossRef]
- Lim, W.S.; Roh, J.L.; Kim, S.B.; Choi, S.H.; Nam, S.Y.; Kim, S.Y. Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma. Laryngoscope 2017, 127, E437–E442. [Google Scholar] [CrossRef]
- Ishizuka, M.; Fujimoto, Y.; Itoh, Y.; Kitagawa, K.; Sano, M.; Miyagawa, Y.; Ando, A.; Hiramatsu, M.; Hirasawa, N.; Ishihara, S.; et al. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin. Jpn. J. Clin. Oncol. 2011, 41, 973–979. [Google Scholar] [CrossRef]
SI Component | Low Risk | High Risk |
---|---|---|
T classification | T1 and T2 | T3 and T4 |
N classification | N0 | N+ |
OL | Tumor inferior to OL | Tumor superior and/or across the OL |
NLR | ≤3 | >3 |
BMI | ≥25 | <25 |
Albumin | ≥35 g/dL | <35 g/dL |
Low SI (n = 24) | High SI (n = 27) | Cohort (n = 51) | |
---|---|---|---|
Age | |||
Mean, years | 58.7 | 61.4 | 60.1 |
SD, years | 12.9 | 14.6 | 12.9 |
Sex, n/% | |||
M | 18/75.0 | 15/55.6 | 33/64.7 |
F | 6/25.0 | 12/44.4 | 18/35.3 |
T classification, n/% | |||
T1 | 9/37.5 | 0/0.0 | 9/17.6 |
T2 | 7/29.2 | 2/7.4 | 9/17.6 |
T3 | 1/4.2 | 5/18.5 | 6/11.8 |
T4 | 7/29.2 | 19/70.4 | 26/51.0 |
Tx | 0/0.0 | 1/3.7 | 1/2.0 |
N classification, n/% | |||
N0 | 22/91.7 | 18/66.7 | 40/78.4 |
N1 | 0/0.0 | 0/0.0 | 0/0.0 |
N2 | 1/4.2 | 7/25.9 | 8/15.7 |
N3 | 0/0.0 | 1/3.7 | 1/2.0 |
Nx | 1/4.2 | 1/3.7 | 2/3.9 |
M classification, n/% | |||
M0 | 23/95.8 | 26/96.3 | 49/96.1 |
M1 | 1/4.2 | 1/3.7 | 2/3.9 |
Primary therapy, n/% | |||
Surgery | 18/75.0 | 9/33.3 | 27/52.9 |
Radio ± chemotherapy | 6/25.0 | 18/66.7 | 24/47.1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brkic, F.F.; Stoiber, S.; Al-Gboore, S.; Quint, C.; Schnoell, J.; Scheiflinger, A.; Heiduschka, G.; Brunner, M.; Kadletz-Wanke, L. Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma. Nutrients 2022, 14, 4337. https://doi.org/10.3390/nu14204337
Brkic FF, Stoiber S, Al-Gboore S, Quint C, Schnoell J, Scheiflinger A, Heiduschka G, Brunner M, Kadletz-Wanke L. Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma. Nutrients. 2022; 14(20):4337. https://doi.org/10.3390/nu14204337
Chicago/Turabian StyleBrkic, Faris F., Stefan Stoiber, Sega Al-Gboore, Clemens Quint, Julia Schnoell, Alexandra Scheiflinger, Gregor Heiduschka, Markus Brunner, and Lorenz Kadletz-Wanke. 2022. "Evaluation of the Prognostic Capacity of a Novel Survival Marker in Patients with Sinonasal Squamous Cell Carcinoma" Nutrients 14, no. 20: 4337. https://doi.org/10.3390/nu14204337